nach oben

Erschienen in:

01.07.2010 | Original Article

Role of ¹¹C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy

verfasst von: Chiara Fuccio, Paolo Castellucci, Riccardo Schiavina, Ivan Santi, Vincenzo Allegri, Vincenzina Pettinato, Stefano Boschi, Giuseppe Martorana, Adil Al-Nahhas, Domenico Rubello, Stefano Fanti

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim

To assess the utility of ¹¹C-choline PET/CT in the restaging of prostate cancer (PC) patients who showed a single finding on bone scintigraphy (BS) that was classified as equivocal or suspected for metastatic lesion.

Materials and methods

A total of 25 PC patients with biochemical failure (mean PSA value 11.1 ng/mL; median value 6.3 ng/mL; range 0.2–37.7 ng/mL) after primary treatment were included in this retrospective study. All of them showed a single lesion on BS reported as suspected for metastatic lesion or as equivocal finding. Patients underwent ¹¹C-choline PET/CT within 1–4 months from BS. Validation was established by follow-up for at least 6 months.

Results

On the basis of biopsy confirmation and/or 6-month follow-up, 22 of 25 patients were classified as positive for the presence of metastatic bone lesions: 13 with a single lesion and 9 with multiple lesions. ¹¹C-choline PET/CT was positive in 19/25 patients and, on a lesion basis, it showed 50 positive findings. BS results were confirmed in 8/25 (32%) patients. ¹¹C-choline PET/CT detected multiple sites of relapse in 11/25 (44%) patients: in 2/11, a single bone lesion associated with other extraosseous sites of relapse; in 6/11, multiple bone lesions; in 3/11, multiple bone lesions and other extraosseous localizations. Finally, 6/25 patients were negative on ¹¹C-choline PET/CT. In 3/6 patients, an osteoblastic lesion was seen on CT attenuation correction images (PET false negative; BS true positive), while in 3/6 patients only findings suggestive of the presence of degenerative disease were found (PET true negative; BS false positive). On a patient basis, ¹¹C-choline PET/CT showed a diagnostic sensitivity of 86% (19/22) and a specificity of 100% (19/19).

Conclusions

In our study, ¹¹C-choline PET/CT detected unknown lesions in 11/25 patients. Patients with a single equivocal finding on BS could have important additional information from ¹¹C-choline PET/CT study, especially in the detection of additional metastases, to choose an appropriate treatment.

Fanti S, Nanni C, Ambrosini V, Gross MD, Rubello D, Farsad M. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging. 2007;51(3):260–71.PubMed

Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736–41.CrossRefPubMed

Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–23.CrossRefPubMed

Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(20):380–5.PubMed

Roberts SG, Blute ML, Bergstralh EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76(6):576–81.CrossRefPubMed

Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.CrossRefPubMed

Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991;68:74–80.CrossRefPubMed

Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–94.CrossRefPubMed

Choueiri TK, Dreicer R, Paciorek A, et al. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179(3):906–10.CrossRefPubMed

10.

Bott SR. Prostate cancer: management of recurrent disease after radical prostatectomy. Prostatic Dis. 2004;7:211–6.CrossRef

11.

Kramer S, Gorich J, Gottfried HW, et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol. 1997;70:995–9.PubMed

12.

Cher ML, Bianco FJ, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387–91.CrossRefPubMed

13.

Gomez P, Manoharan M, Kim SS, et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2004;94:299–302.CrossRefPubMed

14.

Krause BJ, Souvatzoglou M, Tincel M, et al. The detection rate of 11-C choline PET/TC depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23.CrossRefPubMed

15.

De Jong I, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. ¹¹C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32–8.CrossRefPubMed

16.

Cimitan M, Bortolus R, Morassut S, et al. [18]F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–98.CrossRefPubMed

17.

Hara T, Kosaka N, Kishi H, et al. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–5.PubMed

18.

Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate cancer. Eur J Nucl Med. 2000;27:1415–9.CrossRefPubMed

19.

Zeisel SH. Dietary choline: biochemistry, physiology and pharmacology. Annu Rev Nutr. 1981;1:95–121.CrossRefPubMed

20.

Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61(9):3599–603.PubMed

21.

Sutinen E, Nurmi M, Roivainer A, et al. Kinetics of ¹¹C-choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2003;31:317–24.CrossRefPubMed

22.

Muller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide, docetaxel treatment. Eur J Nucl Med Mol Imaging. 2009;36(9):1434–42.CrossRefPubMed

23.

Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. Int J Urol. 2007;14(2):89–95.CrossRefPubMed

24.

Clark JC, Dass CR, Choong PF. Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008;13(4):609–27.CrossRefPubMed

25.

Campa JA III, Payne R. The management of intractable bone pain: a clinician’s perspective. Semin Nucl Med. 1992;22:3–10.CrossRefPubMed

26.

Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol. 2006;24(1):4–12.PubMed

27.

Pascali C, Bogni A, Iwata R, et al. ¹¹C-methylation on C18 SepPak cartridge : a convenient way to produce [N-methyl-¹¹C] choline. J Labelled Compds Radiopharm. 2000;49:195–203.CrossRef

28.

Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol. 2006;49(3):429–40.CrossRefPubMed

29.

Dasgeb B, Mulligan MH, Kim CK. The current status of bone scintigraphy in malignant disease. Semin Muscoloskelet radiol. 2007;11(4):301–11.CrossRef

30.

Cooperberg MR, Lubeck DP, Grossfeld GD, et al. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002;168:491–5.CrossRefPubMed

31.

O’Sullivan JM, Norman AR, Cook GJ, et al. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int. 2003;92:685–9.CrossRefPubMed

32.

Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am. 1993;20:705–11.PubMed

33.

Wymenga LF, Boomsma JH, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001;88:226–30.CrossRefPubMed

34.

Akin O, Hricak H. Imaging of prostate cancer. Radiol Clin North Am. 2007;45(1):167–82.CrossRefPubMed

35.

Schöder H, Herrmann K, Gönen M, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11(13):4761–9.CrossRefPubMed

36.

Oyama N, Miller TR, Dehdashti F, et al. ¹¹C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44(4):556–8.

37.

Picchio M, Messa C, Landoni C, et al. Value of [¹¹C]choline positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose positron emission tomography. J Urol. 2003;169:1337–40.CrossRefPubMed

38.

Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50(9):1394–400.CrossRefPubMed

39.

Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Imaging Biol. 2009;11(6):446–54.CrossRef

40.

Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35(10):1766–74.CrossRefPubMed

Titel: Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy
verfasst von: Chiara Fuccio
Paolo Castellucci
Riccardo Schiavina
Ivan Santi
Vincenzo Allegri
Vincenzina Pettinato
Stefano Boschi
Giuseppe Martorana
Adil Al-Nahhas
Domenico Rubello
Stefano Fanti
Publikationsdatum: 01.07.2010
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 6/2010
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-010-0390-x

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Role of ¹¹C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy

Abstract

Aim

Materials and methods

Results

Conclusions

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Aim

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Prevalence of positive FDG-PET findings in patients with high CEA levels

Takotsubo cardiomyopathy following dipyridamole pharmacologic stress

18F-FDG PET/CT findings of pharyngeal tuberculosis

SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement

The assessment of bee venom responses in an experimental model of mono-arthritis using Tc-99m DPD bone scintigraphy

Relationship between exercise capacity and cardiac diastolic function assessed by time–volume curve from 16-frame gated myocardial perfusion SPECT